Trending...
- California: Governor Newsom announces appointments 9.10.25 - 385
- John Thomas calls for unity and prayer after tragic loss - 353
- Ayurveda, Ayurvedic medical Science and Ayurvedic Therapies, Dr.Abhay Kumar Pati - 348
SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc. (NYSE American: CLDI or "Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the issuance of a new patent for the company's SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic. In addition, the company also provided an update on the timing of its anticipated clinical milestones.
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,655,455 titled, "Enhanced systems for cell-mediated oncolytic viral therapy," directed to Calidi's SuperNova platform composed of adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus.
"This latest patent granted to Calidi covering meaningful features of our SuperNova platform represents an important milestone as we prepare to advance CLD-201 into the clinic," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. "We are pleased to continue strengthening an already robust intellectual property portfolio, and feel we are well-positioned to capture the potential of our efforts to develop a universal and off-the-shelf SuperNova platform to radically transform the landscape for patients with advanced solid tumors."
The patent covers a composition where cells are incubated with an oncolytic virus for a defined period allowing the expression of at least one immunomodulatory protein or recombinant therapeutic protein encoded by the virus, by virtue of association of the virus, with the carrier cell. Early Calidi research has shown the potential ability of the SuperNova platform to shield the viral payload from the immune system, supporting efficient delivery to tumor sites and effectively potentiating oncolytic viruses' therapeutic efficacy.
More on The Californer
"We see great potential in our SuperNova technology to address the vast unmet need for effective treatments of solid tumor cancers," said Dr. Antonio F. Santidrian, Chief Scientific Officer at Calidi Biotherapeutics. "We look forward to initiating our first-in-human clinical trial of our off-the-shelf and allogeneic therapy in 2024."
In addition, Calidi also provided updates on the timing for certain anticipated clinical milestones for its NeuroNova and SuperNova platforms.
Anticipated Clinical Milestones
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
More on The Californer
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as "anticipates," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predicts," "project," "should," "towards," "would" as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. Any forward-looking statements contained in this discussion, including but not limited to statements listed in "Anticipated Clinical Milestones," and statements concerning the safety and efficacy of our product candidate CLD-201 are based on Calidi's current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Calidi will be those that it has anticipated. Any forward-looking statements involve a number of risks, uncertainties (some of which are beyond Calidi's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Other risks and uncertainties are set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's Registration Statements filed with the SEC on Form S-4 filed on August 2, 2023, on Form S-1 filed on October 6, 2023 and Form 10-Q filed on November 14, 2023.
Contacts
For Investors:
Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com
For Media:
Gwen Gordon
gwen@gwengordonpr.com
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,655,455 titled, "Enhanced systems for cell-mediated oncolytic viral therapy," directed to Calidi's SuperNova platform composed of adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus.
"This latest patent granted to Calidi covering meaningful features of our SuperNova platform represents an important milestone as we prepare to advance CLD-201 into the clinic," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. "We are pleased to continue strengthening an already robust intellectual property portfolio, and feel we are well-positioned to capture the potential of our efforts to develop a universal and off-the-shelf SuperNova platform to radically transform the landscape for patients with advanced solid tumors."
The patent covers a composition where cells are incubated with an oncolytic virus for a defined period allowing the expression of at least one immunomodulatory protein or recombinant therapeutic protein encoded by the virus, by virtue of association of the virus, with the carrier cell. Early Calidi research has shown the potential ability of the SuperNova platform to shield the viral payload from the immune system, supporting efficient delivery to tumor sites and effectively potentiating oncolytic viruses' therapeutic efficacy.
More on The Californer
- City of Long Beach Launches Second Cohort of Urban Planning and Design Internship Program
- California: Governor Newsom launches new statewide service effort to support the well-being of young men
- California: Governor, First Partner statement on the passing of Robert Redford
- 'The Lonely Diners Club' Goes Into Pre-Production
- Tour Napa Like a Local: Vines of Napa Valley Wine Passport AKA Vine Pass Unlocks Hidden Gems
"We see great potential in our SuperNova technology to address the vast unmet need for effective treatments of solid tumor cancers," said Dr. Antonio F. Santidrian, Chief Scientific Officer at Calidi Biotherapeutics. "We look forward to initiating our first-in-human clinical trial of our off-the-shelf and allogeneic therapy in 2024."
In addition, Calidi also provided updates on the timing for certain anticipated clinical milestones for its NeuroNova and SuperNova platforms.
Anticipated Clinical Milestones
- 1H 2024: First patient dosed in CLD-101 (NeuroNova) Phase 1b/2 trial in collaboration with Northwestern University for newly diagnosed high-grade glioma patients
- 2H 2024: First patient dosed in CLD-201 (SuperNova) Phase 1 trial
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
More on The Californer
- Changzhou Huifeng Vehicle Parts Factory Continues Participation 2025 AAPEX Show at Las Vegas
- Dental Surgical Center Accepts Sedation Patients with Medicaid for MD, WV, PA and DC
- Attn: Business: Looking for ways to Increase your Sales and Profit? Start using this Marketing Math
- END WELL 2025 SUMMIT BRINGS "RADICAL BRAVERY" TO LOS ANGELES, FEATURING EMMA HEMING WILLIS AND YVETTE NICOLE BROWN AMONG LEADING VOICES IN END-OF-LIFE TRANSFORMATION
- Long Beach: City to Host Community Demo Day to Showcase Neighborhood Technology Solutions
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as "anticipates," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predicts," "project," "should," "towards," "would" as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. Any forward-looking statements contained in this discussion, including but not limited to statements listed in "Anticipated Clinical Milestones," and statements concerning the safety and efficacy of our product candidate CLD-201 are based on Calidi's current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Calidi will be those that it has anticipated. Any forward-looking statements involve a number of risks, uncertainties (some of which are beyond Calidi's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Other risks and uncertainties are set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's Registration Statements filed with the SEC on Form S-4 filed on August 2, 2023, on Form S-1 filed on October 6, 2023 and Form 10-Q filed on November 14, 2023.
Contacts
For Investors:
Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com
For Media:
Gwen Gordon
gwen@gwengordonpr.com
Filed Under: Business
0 Comments
Latest on The Californer
- New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle'
- AdamMoney Launches Nationwide Hiring for Remote Sales Representatives to Promote 1st of-Its-Kind Pr
- Elevate Unveils GroundComm X30 at 2025 International GSE Expo in Las Vegas
- California: Governor Gavin Newsom to launch new statewide effort to support the well-being of young men
- Descryber Launches Innovative Web App to Simplify DIY Trademark Applications
- LVN Jobs in LA Connects Licensed Vocational Nurses with Top LVN Staffing Jobs in Los Angeles
- California-based productions win big at Emmy Awards
- White Glove Restoration Expands 24/7 Emergency Response Team Across San Diego County
- Marin's Rising Star Easton Cain Revives American Regionalism in the Bay Area
- City of Long Beach Launches Redesigned Jobs Webpage
- Cabrillo Economic Development Corporation Celebrates Completion of Dolores Huerta Gardens
- Lightning Motorcycle's Next-Gen Prototype Hits 174 MPH on Its Lowest Performance Setting
- Long Beach Health Department Launches Early Childhood Mental Health Program to Support Families and Childcare Providers
- Dane Flanigan joins Raymond James in Pasadena as Financial Advisor
- Governor Newsom announces appointments, including new California Air Resources Board Chair
- Legendary Mitchell-Hedges Crystal Skull Arrives in Beverly Hills
- NEW power supply release from Kepco Dynatronix - HSP Advanced
- St. Augustine Honors Hispanic Heritage Month
- WesternU researchers show Osteopathic Manipulative Treatment improves efficacy of COVID-19 vaccine
- Vesica Health Receives AUA Guideline Inclusion